ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

Market Cap	2.46B +9.6%
Revenue (ttm)	862.85M +2.9%
Net Income	17.80M -48.1%
EPS	0.07 -48.8%
Shares Out	256.06M
PE Ratio	132.87
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,076,340
Open	9.48
Previous Close	9.62
Day's Range	9.21 - 9.65
52-Week Range	9.04 - 15.20
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsule...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,196
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300254

Financial Performance

In 2025, SHE:300254's revenue was 870.79 million, an increase of 2.86% compared to the previous year's 846.61 million. Earnings were 24.85 million, a decrease of -41.10%.